Weekly low dose epirubicin in elderly cancer patients

Dario Nicolella, Giuseppe Grimaldi, Giuseppe Colantuoni, Mario Belli, Giuseppe Frasci, John Perchard, Pasquale Comella

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aims and background: The treatment of elderly patients with metastatic solid tumours is still a debated problem. Patients over 75 years are generally excluded from combination chemotherapy trials because of higher toxicity. Several clinical studies have shown that weekly low dose epirubicin is a well tolerated and effective treatment for elderly cancer patients (breast, prostate, lung). Methods: We report a study of patients aged between 75 and 85 years affected by metastatic anthracyclines-sensible carcinomas, to assess the tolerance of epirubicin given weekly at a dose of 25 mg/m2. Results: 25 patients (13 males, 12 females; ECOG P.S. 0-2) entered the study and were evaluable for side effects. One-hundred and ninety-six cycles of therapy have been administered. Side effects were never severe. Mucositis (9 patients), leucopenia (7 patients), anemia (5 patients) were usually of grade 1 or 2. Grade 1 cardiotoxicity (tachycardia) was observed in only one case. Grade 3 toxicity consisted of anemia (1 patient) and mucositis (1 patient), while grade 4 toxicity never occurred. Nineteen patients were evaluable for response: 0 CR, 4 PR (1 lung, 3 breast), 8 SD (3 lung, 3 breast, 2 prostate) have been observed. Compliance was encouraging and the majority of patients showed a decrease in symptoms and an improvement in performance status. Conclusions: Weekly low-dose epirubicin is a very well tolerated treatment in elderly cancer patients. In view of the negligible toxicity encountered, it could be of utility to test this regimen in patients aged 75 years or older, affected by anthracyclines-sensible metastatic tumors, also to assess activity.

Original languageEnglish
Pages (from-to)369-371
Number of pages3
JournalTumori
Volume82
Issue number4
Publication statusPublished - Jul 1996

Fingerprint

Epirubicin
Neoplasms
Mucositis
Anthracyclines
Lung
Anemia
Prostate
Breast
Leukopenia
Therapeutics
Combination Drug Therapy
Tachycardia
Compliance

Keywords

  • elderly tumors
  • epirubicin
  • weekly monochemotherapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Nicolella, D., Grimaldi, G., Colantuoni, G., Belli, M., Frasci, G., Perchard, J., & Comella, P. (1996). Weekly low dose epirubicin in elderly cancer patients. Tumori, 82(4), 369-371.

Weekly low dose epirubicin in elderly cancer patients. / Nicolella, Dario; Grimaldi, Giuseppe; Colantuoni, Giuseppe; Belli, Mario; Frasci, Giuseppe; Perchard, John; Comella, Pasquale.

In: Tumori, Vol. 82, No. 4, 07.1996, p. 369-371.

Research output: Contribution to journalArticle

Nicolella, D, Grimaldi, G, Colantuoni, G, Belli, M, Frasci, G, Perchard, J & Comella, P 1996, 'Weekly low dose epirubicin in elderly cancer patients', Tumori, vol. 82, no. 4, pp. 369-371.
Nicolella D, Grimaldi G, Colantuoni G, Belli M, Frasci G, Perchard J et al. Weekly low dose epirubicin in elderly cancer patients. Tumori. 1996 Jul;82(4):369-371.
Nicolella, Dario ; Grimaldi, Giuseppe ; Colantuoni, Giuseppe ; Belli, Mario ; Frasci, Giuseppe ; Perchard, John ; Comella, Pasquale. / Weekly low dose epirubicin in elderly cancer patients. In: Tumori. 1996 ; Vol. 82, No. 4. pp. 369-371.
@article{0a3a679fbca34b9aaef3e8345ca74f46,
title = "Weekly low dose epirubicin in elderly cancer patients",
abstract = "Aims and background: The treatment of elderly patients with metastatic solid tumours is still a debated problem. Patients over 75 years are generally excluded from combination chemotherapy trials because of higher toxicity. Several clinical studies have shown that weekly low dose epirubicin is a well tolerated and effective treatment for elderly cancer patients (breast, prostate, lung). Methods: We report a study of patients aged between 75 and 85 years affected by metastatic anthracyclines-sensible carcinomas, to assess the tolerance of epirubicin given weekly at a dose of 25 mg/m2. Results: 25 patients (13 males, 12 females; ECOG P.S. 0-2) entered the study and were evaluable for side effects. One-hundred and ninety-six cycles of therapy have been administered. Side effects were never severe. Mucositis (9 patients), leucopenia (7 patients), anemia (5 patients) were usually of grade 1 or 2. Grade 1 cardiotoxicity (tachycardia) was observed in only one case. Grade 3 toxicity consisted of anemia (1 patient) and mucositis (1 patient), while grade 4 toxicity never occurred. Nineteen patients were evaluable for response: 0 CR, 4 PR (1 lung, 3 breast), 8 SD (3 lung, 3 breast, 2 prostate) have been observed. Compliance was encouraging and the majority of patients showed a decrease in symptoms and an improvement in performance status. Conclusions: Weekly low-dose epirubicin is a very well tolerated treatment in elderly cancer patients. In view of the negligible toxicity encountered, it could be of utility to test this regimen in patients aged 75 years or older, affected by anthracyclines-sensible metastatic tumors, also to assess activity.",
keywords = "elderly tumors, epirubicin, weekly monochemotherapy",
author = "Dario Nicolella and Giuseppe Grimaldi and Giuseppe Colantuoni and Mario Belli and Giuseppe Frasci and John Perchard and Pasquale Comella",
year = "1996",
month = "7",
language = "English",
volume = "82",
pages = "369--371",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Weekly low dose epirubicin in elderly cancer patients

AU - Nicolella, Dario

AU - Grimaldi, Giuseppe

AU - Colantuoni, Giuseppe

AU - Belli, Mario

AU - Frasci, Giuseppe

AU - Perchard, John

AU - Comella, Pasquale

PY - 1996/7

Y1 - 1996/7

N2 - Aims and background: The treatment of elderly patients with metastatic solid tumours is still a debated problem. Patients over 75 years are generally excluded from combination chemotherapy trials because of higher toxicity. Several clinical studies have shown that weekly low dose epirubicin is a well tolerated and effective treatment for elderly cancer patients (breast, prostate, lung). Methods: We report a study of patients aged between 75 and 85 years affected by metastatic anthracyclines-sensible carcinomas, to assess the tolerance of epirubicin given weekly at a dose of 25 mg/m2. Results: 25 patients (13 males, 12 females; ECOG P.S. 0-2) entered the study and were evaluable for side effects. One-hundred and ninety-six cycles of therapy have been administered. Side effects were never severe. Mucositis (9 patients), leucopenia (7 patients), anemia (5 patients) were usually of grade 1 or 2. Grade 1 cardiotoxicity (tachycardia) was observed in only one case. Grade 3 toxicity consisted of anemia (1 patient) and mucositis (1 patient), while grade 4 toxicity never occurred. Nineteen patients were evaluable for response: 0 CR, 4 PR (1 lung, 3 breast), 8 SD (3 lung, 3 breast, 2 prostate) have been observed. Compliance was encouraging and the majority of patients showed a decrease in symptoms and an improvement in performance status. Conclusions: Weekly low-dose epirubicin is a very well tolerated treatment in elderly cancer patients. In view of the negligible toxicity encountered, it could be of utility to test this regimen in patients aged 75 years or older, affected by anthracyclines-sensible metastatic tumors, also to assess activity.

AB - Aims and background: The treatment of elderly patients with metastatic solid tumours is still a debated problem. Patients over 75 years are generally excluded from combination chemotherapy trials because of higher toxicity. Several clinical studies have shown that weekly low dose epirubicin is a well tolerated and effective treatment for elderly cancer patients (breast, prostate, lung). Methods: We report a study of patients aged between 75 and 85 years affected by metastatic anthracyclines-sensible carcinomas, to assess the tolerance of epirubicin given weekly at a dose of 25 mg/m2. Results: 25 patients (13 males, 12 females; ECOG P.S. 0-2) entered the study and were evaluable for side effects. One-hundred and ninety-six cycles of therapy have been administered. Side effects were never severe. Mucositis (9 patients), leucopenia (7 patients), anemia (5 patients) were usually of grade 1 or 2. Grade 1 cardiotoxicity (tachycardia) was observed in only one case. Grade 3 toxicity consisted of anemia (1 patient) and mucositis (1 patient), while grade 4 toxicity never occurred. Nineteen patients were evaluable for response: 0 CR, 4 PR (1 lung, 3 breast), 8 SD (3 lung, 3 breast, 2 prostate) have been observed. Compliance was encouraging and the majority of patients showed a decrease in symptoms and an improvement in performance status. Conclusions: Weekly low-dose epirubicin is a very well tolerated treatment in elderly cancer patients. In view of the negligible toxicity encountered, it could be of utility to test this regimen in patients aged 75 years or older, affected by anthracyclines-sensible metastatic tumors, also to assess activity.

KW - elderly tumors

KW - epirubicin

KW - weekly monochemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029824485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029824485&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 369

EP - 371

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -